Table 2 Genetic association results of the leading genetic variants identified in the GWAS for time to COVID-19 symptom remission.

From: Genetics of symptom remission in outpatients with COVID-19

Leading variant

Nearest coding genes

Effect allele

Effect allele frequency

Study arm

N total

N events (%)

HR (95% CI)

P value

Interaction

P value*

rs1173773

chr5:32750877:T:C

NPR3

C

0.34

Placebo

851

627 (73.7%)

1.32 (1.18–1.48)

1.17 × 10–6

0.18

Colchicine

872

627 (71.9%)

1.18 (1.05–1.32)

6.30 × 10–3

All

1723

1254 (72.8%)

1.25 (1.15–1.35)

4.94 × 10–8

–

rs62575331

chr9:115647521:C:G

DEC1/PAPPA

G

0.12

Placebo

851

627 (73.7%)

1.57 (1.34–1.84)

2.95 × 10–8

1.19 × 10–5

Colchicine

872

627 (71.9%)

0.87 (0.72–1.05)

0.15

All

1723

1254 (72.8%)

1.19 (1.05–1.34)

5.80 × 10–3

–

  1. Chr: chromosome; HR: hazard ratio; N: number of patients. Effect allele frequency in the study population. Reported results are for Cox proportional hazards regression adjusted for age, sex, and 10 principal components for genetic ancestry; and for the analysis of rs1173773, with additional adjustment for study arm. *Interaction P value for the variant by colchicine interaction term. Chromosomal positions are according to GRCh38.
Back to article page